A Novel Naphthoquinone-Coumarin Hybrid That Inhibits BCR-ABL1-STAT5 Oncogenic Pathway and Reduces Survival in Imatinib-Resistant Chronic Myelogenous Leukemia Cells
BCR-ABL1-STAT5 is an oncogenic signaling pathway in human chronic myelogenous leukemia (CML) and it represents a valid target for anti-CML drug design. Resistance to direct BCR-ABL1 inhibitors is a common clinical issue, so STAT5 inhibition has become an interesting alternative target. In this study...
Saved in:
Main Authors: | Patricia Martín-Rodríguez (Author), Borja Guerra (Author), Idaira Hueso-Falcón (Author), Haidee Aranda-Tavío (Author), Juan Díaz-Chico (Author), José Quintana (Author), Francisco Estévez (Author), Bonifacio Díaz-Chico (Author), Angel Amesty (Author), Ana Estévez-Braun (Author), Leandro Fernández-Pérez (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2019-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Fluorescence in situ hybridization patterns of BCR/ABL1 fusion in chronic myelogenous leukemia at diagnosis
by: Poonam P Jain, et al.
Published: (2012) -
Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia
by: Aypara Hasanova, et al.
Published: (2023) -
Overcoming the imatinib-resistant BCR-ABL mutants with new ureidobenzothiazole chemotypes endowed with potent and broad-spectrum anticancer activity
by: Ashraf K. El-Damasy, et al.
Published: (2023) -
Synthesis and identification of GZD856 as an orally bioavailable Bcr-AblT315I inhibitor overcoming acquired imatinib resistance
by: Xiaoyun Lu, et al.
Published: (2017) -
Synergistic cytotoxicity from combination of imatinib and platinum-based anticancer drugs specifically in Bcr-Abl positive leukemia cells
by: Yuming Wei, et al.
Published: (2015)